Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
RNS: "Submission to EPA & subsidiary incorporated in USA Tristel incorporates a wholly-owned subsidiary in Delaware, USA, and makes a submission to the Environmental Protection Agency for its Duo chlorine dioxide disinfection foam Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has established its presence in the United States by incorporating a wholly-owned subsidiary in the State of Delaware. This initiative is part of the Company's stated intention to enter the North American infection prevention market. This plan was unveiled in the Company's preliminary results announcement in October 2015. In pursuit of this plan, on 30 June 2017 Tristel made a submission for regulatory clearance by the Environmental Protection Agency ("EPA") of its Duo chlorine dioxide disinfection foam. The Company expects to receive approval in the second half of its financial year commencing 1 July 2017. Following EPA federal approval, the Company will then need to secure state-by-state approval before it can commence selling Duo. The EPA clearance will enable Duo to claim intermediate disinfection of all non-porous surfaces, including those of medical instruments. This is Tristel's core activity worldwide and accounts for approximately 80% of the Company's revenues. In addition, the Company continues to develop two submissions to be made to the Food and Drug Administration (FDA) for 510(K) clearance in respect of Duo. The 510(K) approval will permit Duo to claim high-level disinfection of medical instruments. Tristel expects to complete and make these submissions during the first half of its financial year commencing 1 July 2018. In all other markets worldwide, Duo is classified as a high-level disinfectant. It is important to note that there is no difference in formulation or performance of the Duo product submitted to the EPA and the Duo product that will be submitted to the FDA in due course. The Company continues to develop a further four additional submissions to be made to the EPA during the coming 12 months for other products selected from its global portfolio. These products are also chlorine dioxide based. Paul Swinney, CEO, comments: "We are very pleased with the progress that our team has made in reaching our first major milestone to enter the North American infection prevention market - a submission to the EPA for approval of our Duo chlorine dioxide foam. Attaining this milestone keeps us on track to achieve our objective of generating revenues in the North American market during the 2018-19 financial year. "Duo has patent protection in both the United States and Canada. "We are now formulating our manufacturing and distribution strategy for North America and will provide further detail at the time of our preliminary results announcement in October.""
Probable trading update, anything material has to be announced asap so not expecting major news. Happy with progress and it seems so is everyone else. Hospitals seem to like Tristel along with other users, googled it at the weekend and found sprays at around £50 a pop on a tattoing website. Cheap to avoid being sued. Watched a prog on iplayer about superbugs too, Jesus some nasty stuff out there and a shortage of new antibiotics.
Yes.......... And about the noise: - so you should be!! Look what you did.... :)
We can only guess, might be an institution; might be another company taking a stake; might be an individual taking a stake after hearing about US FDA/EPA approvals. Whatever it is the buyer seems to have deep pockets but this is a quality company that you don't see often enough and quality costs. Return on Capital 26.3 % Return on Equity 23.5 % Operating Margin 20.2 % Earnings per share growth of 16.2% Unusual to have a share on AIM which makes money and has a massive market to go for, patent protected technology and pays a dividend. PS sorry about all the noise.
Post recd !!!! Don't mind being in same sentence!!! Don't think im in the same shares as him though! As for tstl..... just keeps going.. £2 on the cards
I get what you mean, Ezhik. Since about the same time I've been taking a course in how to invest - or not to invest - in AIM shares. Expensive course!! Some winners, some losers. As for pavements, I've done quite well out of them with BREE. It's been oil with THAL, fintech with TUNG, mining with WLFE that have cost me. Shan and Philip Hammond are right: boring is good. I hope Shan can stand being mentioned in the same sentence!
Move along nothing to see here!
Yeah, well I bought these in 2013, if I just put my money here instead of chasing pavements, I would have about half a million instead of half a sixpence. Other shares bought in 2013 are now down 97 % . You just never know.
It's true They do! Over the years I have seen many wonderful little gem companies slowly rising away without the bells and whistles of elaborate rns statements Tstl, som, dwht, sdm, abdp, ton et al and many others!
Oh dear. Apple can't spell.
i'm beginning to think the best shares have the quietist boards. Nice!
Two interesting trades today 09-Mar-17 07:00:14 191.00p 25,000 Buy* £47.75k - a record sp for TSTL 09-Mar-17 12:14:37 190.00p 25,000 Buy* £47.50k
I doubt that this share price will double and treble in the next year or two, but I think it will continue it's steady trend and pay us handsomely. It's great to see that the UK is still progressing, even though there must be limits to that, and even better to see that the overseas sales are growing so fast. That's really good, and if all goes well with regard to the US then things really could take off. Just hope the White House avoids the DT's.... For me, definitely one to hold on to.
If you would like to hear management present the interim results for Tristel we will be hosting a webinar on Thursday 23rd February at 12.15pm. Paul Swinney, Chief Executive, and Liz Dixon, Finance Director, will give a presentation lasting approximately 30 mins and there will then be an opportunity for Q&A. To join please register at: https://attendee.gotowebinar.com/register/3357486679009407235 If you would like to submit any questions for management ahead of the meeting please send them to ben.ferguson@equitydevelopment.co.uk Kind regards, The Equity Development Team
Thanks all.
Anyone know what gives? Damned by faint praise??
Reducing infections in the NHS - https://www.gov.uk/government/news/reducing-infections-in-the-nhs The government’s plans to prevent NHS infections include: •more money for hospitals making the most progress in reducing infection rates with a new £45 million quality premium Alongside the plan to reduce E. coli rates, an additional £60 million will be allocated to the ‘Getting It Right First Time’ programme. First pioneered by Professor Tim Briggs in orthopaedics, the programme will now be expanded to another 18 surgical specialties, building on the initial investment of £2.5 million.
A recording of Tuesday's webinar is now available at: https://www.youtube.com/watch?v=lGo5RtU3IlY Thanks, The Equity Development team
Another great set of figures and more to come imo. USA and Canada looking good!
If you would like to hear management present the results for Tristel we will be hosting a webinar on Tuesday 18th October at 12.30pm. Paul Swinney, Chief Executive, and Liz Dixon, Finance Director, will give a presentation lasting approximately 30 mins and there will then be an opportunity for Q&A. To join please register at: https://attendee.gotowebinar.com/register/4859093004964327683 If you would like to submit any questions for management ahead of the meeting please send them to ben.ferguson@equitydevelopment.co.uk Kind regards, The Equity Development Team
was the new high at 09:06. Am now too tempted and going to see about lumping off, trouble is getting my volume away.. Still no concrete news out there, so probably opting for "sell on rumour" principle - time will tell if wise or not but having doubled my money since Feb 2015 I think it is time to cash in.
just paid - record for TSTL. Demand there again this am. Good dividends. Revenues steadily increasing. Exports increasing. Bugs not getting any nicer. USA licences on the horizon.
Thanks Seadoc, I had feelers out everywhere I could yesterday and best conclusion isperhaps some leaky speculation about progress in the US. I was very tempted to offload my lump at 1.525 but resisted as demand far outstripped supply for shares at the time - but SP fell back a bit by end of day. Fingers crossed I made the right call then......
Anyone any info on what's driving the SP up at the moment ? Can't see anything via Google but we are at new highs so something is driving it.
- - of bugs on the run for their life